8-K: Erasca Reports Clinical Progress for RAS-Targeting Franchise

Erasca, Inc. announced significant clinical progress for its RAS-targeting franchise, including ERAS-0015 and ERAS-4001, and outlined key milestones for 2026-2027.

Summary

• An updated corporate presentation was filed on January 12, 2026, reflecting business and strategic updates.
• Company representatives will present at the J.P. Morgan Healthcare Conference on January 13, 2026.
• ERAS-0015 (Pan-RAS molecular glue): Dose escalation in the AURORAS-1 Phase 1 trial is advancing faster than anticipated due to significant unmet medical need and high investigator and patient enthusiasm.
• ERAS-0015: Ongoing confirmed and unconfirmed responses were observed in multiple patients with differing tumor types and RAS mutations, including two confirmed partial responses (PRs) and one unconfirmed PR at a low dose of 8 mg QD (once per day).
• ERAS-0015: Favorable safety and tolerability were observed, with no dose-limiting toxicities (DLTs) and predominantly low-grade adverse events (AEs) at all dose levels evaluated to date.
• ERAS-0015: Well-behaved, linear pharmacokinetics (PK) were demonstrated across all dose levels evaluated to date, with no observed evidence of exposure plateau.
• ERAS-4001 (Pan-KRAS inhibitor): Dose escalation in the BOREALIS-1 Phase 1 trial continues to advance as expected.
• For naporafenib, a pan-RAF inhibitor for NRASm melanoma, the company is exploring strategic alternatives and has ceased the enrollment of new patients in the Phase 3 SEACRAFT-2 trial.

Sentiment

Score: 7

Explanation: The filing presents strong positive clinical progress for key pipeline assets (ERAS-0015 and ERAS-4001) with promising early efficacy and safety data, and a solid cash runway. However, the cessation of enrollment for naporafenib's Phase 3 trial introduces a notable negative, balancing the overall sentiment.

Positives

• ERAS-0015 AURORAS-1 Phase 1 trial dose escalation is advancing faster than anticipated, underscoring significant unmet medical need and high investigator/patient enthusiasm.
• ERAS-0015 shows ongoing confirmed and unconfirmed responses in multiple patients with diverse tumor types and RAS mutations, including 2 confirmed PRs and 1 unconfirmed PR at a low dose of 8 mg QD.
• ERAS-0015 demonstrates favorable safety and tolerability with no DLTs and predominantly low-grade AEs observed at all doses evaluated.
• ERAS-0015 exhibits well-behaved, linear PK across all doses evaluated, with no evidence of exposure plateau.
• Preclinical data suggests ERAS-0015 has ~5x-10x greater antitumor activity and favorable ADME properties and PK performance compared to the most advanced pan-RAS molecular glue in development (RMC-6236).
• ERAS-0015 shows 8-21x higher binding affinity to cyclophilin A (CYPA) compared to RMC-6236, which may enable more potent RAS inhibition.
• ERAS-4001 dose escalation in the BOREALIS-1 Phase 1 trial is advancing as expected.
• The company maintains a strong financial position with $362 million in cash, cash equivalents, and marketable securities as of September 30, 2025, providing a cash runway into the second half of 2028.

Negatives

• Enrollment of new patients in the Phase 3 SEACRAFT-2 trial for naporafenib has ceased, and the company is exploring strategic alternatives for the program, indicating a setback or deprioritization.

Risks

• Preliminary results of a clinical trial are not necessarily indicative of final results, and one or more clinical outcomes may materially change as patient enrollment continues or more data becomes available.
• An unconfirmed partial response to treatment may not ultimately result in a confirmed partial response after follow-up evaluations.
• Comparisons of clinical observations across different trials involve data from separate trials with distinct designs, patient populations, and methodologies, and therefore may not be directly comparable.
• Forward-looking statements regarding dose-response relationships reflect current expectations and/or assumptions and are subject to risks and uncertainties that could cause actual results to differ materially.
• Assumptions about the development potential of ERAS-0015 and ERAS-4001 are based in large part on preclinical data, and materially and adversely different results may be observed as planned studies and trials are conducted.
• The company's approach to the discovery and development of product candidates based on its singular focus on shutting down the RAS/MAPK pathway is a novel and unproven approach.
• Results from preclinical studies or early clinical trials are not necessarily predictive of future results.
• Assumptions around which programs may have a higher probability of success may not be accurate, potentially leading to the expenditure of limited resources on less promising product candidates or indications.
• Potential delays may occur in the commencement, enrollment, data readout, and completion of clinical trials and preclinical studies.
• The company is dependent on third parties in connection with manufacturing, research, and preclinical and clinical testing.
• Unexpected adverse side effects or inadequate efficacy of product candidates may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims.
• The company may be unable to secure partnerships or other strategic collaborations for naporafenib on acceptable terms or at all.
• There is a risk of inability to realize any benefits from current or future licenses, acquisitions, or collaborations, or to fulfill obligations under such arrangements.
• Regulatory developments in the United States and foreign countries could impact the business.
• The company's ability to obtain and maintain intellectual property protection for its product candidates and maintain its rights under intellectual property licenses is a risk.
• The sufficiency of cash, cash equivalents, and marketable securities to fund operations is a risk, as capital resources may be used sooner than expected.

Future Outlook

Erasca anticipates significant milestones in 2026-2027, including initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 in the first and second halves of 2026, respectively. The company also plans to initiate monotherapy expansion and combination dose escalation cohorts for both programs in the second half of 2026 and 2027, with further data readouts expected in 2027.

Industry Context

Erasca is focused on developing therapies that shut down the RAS/MAPK pathway, a novel and unproven approach in oncology. The company positions ERAS-0015 as a potential best-in-class pan-RAS molecular glue and ERAS-4001 as a potential first-in-class pan-KRAS inhibitor, aiming to address large, underserved markets across multiple tumor types with RAS/MAPK pathway mutations. The competitive landscape for RAS-targeting therapies is active, with several other companies developing pan-RAS and mutant-selective KRAS inhibitors, highlighting the importance of identifying best-in-class candidates.

Comparison to Industry Standards

• ERAS-0015 demonstrated comparable antitumor activity to RMC-6236 (a competitor's pan-RAS molecular glue) at 1/10th of the dose in a sensitive KRAS G12D PDAC CDX model.
• ERAS-0015 showed comparable antitumor activity to RMC-6236 at 1/10th of the dose in an insensitive KRAS G12V NSCLC CDX model.
• ERAS-0015 exhibited 8-21x higher binding affinity to cyclophilin A (CYPA) compared to RMC-6236.
• ERAS-0015 demonstrated significantly more potent inhibition of cell growth across various KRAS mutant cell lines (e.g., 4.5x to 13.4x more potent in several KRAS G12C/D/V/S/Q61R cell lines) compared to RMC-6236.
• ERAS-0015 showed improved bioavailability (%F), lower clearance (CL), and longer half-life (T1/2) in animal species compared to RMC-6236.
• ERAS-0015 demonstrated preferential tumor distribution and longer residence time in vivo compared to RMC-6236.
• Clinical responses for ERAS-0015 were first observed at 8 mg QD, which is 1/10th of the dose observed with RMC-6236 for initial clinical responses.

Stakeholder Impact

• Shareholders/Investors: Positive clinical updates for lead programs could increase investor confidence and potentially share price. The deprioritization of naporafenib might cause some concern but is offset by focus on more promising assets.
• Patients: Promising early clinical data for ERAS-0015 and ERAS-4001 offers hope for new treatment options for RAS-mutant solid tumors, which represent a significant unmet medical need.
• Employees: Strategic shifts, like deprioritizing naporafenib, could lead to reallocation of resources or potential workforce adjustments, though not explicitly stated.
• Partners/Licensors: Continued progress in clinical trials could strengthen existing collaborations and attract new partnerships.

Next Steps

• Presenting at the J.P. Morgan Healthcare Conference on January 13, 2026.
• Posting the updated corporate presentation to the company's website, www.erasca.com.
• Initial Phase 1 monotherapy data for ERAS-0015 in RAS-mutant solid tumors planned for H1 2026.
• Initiation of monotherapy expansion cohorts and combination dose escalation cohorts for ERAS-0015 planned for H2 2026.
• Initial Phase 1 monotherapy data for ERAS-4001 in KRAS-mutant solid tumors planned for H2 2026.
• Monotherapy expansion data and combination dose escalation data for ERAS-0015 planned for 2027.
• Initiation of monotherapy expansion cohorts and combination dose escalation cohorts for ERAS-4001 planned for 2027.

Key Dates

Recommendation

The clinical progress for ERAS-0015, particularly the faster-than-anticipated dose escalation and early signs of efficacy at low doses, is highly encouraging and suggests strong potential for a best-in-class asset. ERAS-4001 also continues to advance as expected. These positives are significant for a clinical-stage biotech. However, the decision to cease enrollment for the naporafenib Phase 3 trial and explore strategic alternatives introduces uncertainty and represents a setback for that specific program. While the company has a solid cash runway, the overall investment thesis is a mix of strong pipeline potential and a recent program deprioritization. A 'hold' recommendation is appropriate to observe further data readouts for ERAS-0015 and ERAS-4001 and gain clarity on the future of the naporafenib program before making a more definitive long-term assessment.

Keywords

Erasca, ERAS-0015, ERAS-4001, RAS-targeting, KRAS inhibitor, molecular glue, oncology, cancer, clinical trial, Phase 1, AURORAS-1, BOREALIS-1, J.P. Morgan Healthcare Conference, biotechnology, pharmaceuticals, solid tumors, RAS/MAPK pathway, naporafenib